AU672862B2 - Cyclodextrin and polymer based drug delivery system - Google Patents

Cyclodextrin and polymer based drug delivery system

Info

Publication number
AU672862B2
AU672862B2 AU56841/94A AU5684194A AU672862B2 AU 672862 B2 AU672862 B2 AU 672862B2 AU 56841/94 A AU56841/94 A AU 56841/94A AU 5684194 A AU5684194 A AU 5684194A AU 672862 B2 AU672862 B2 AU 672862B2
Authority
AU
Australia
Prior art keywords
defined above
alkyl
cyclodextrin
composition
optionally substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU56841/94A
Other languages
English (en)
Other versions
AU5684194A (en
Inventor
Lyle M. Bowman
Sheng-Wan Tsao
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sun Pharmaceutical Industries Inc
Original Assignee
Insite Vision Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US07/984,445 external-priority patent/US5332582A/en
Application filed by Insite Vision Inc filed Critical Insite Vision Inc
Publication of AU5684194A publication Critical patent/AU5684194A/en
Application granted granted Critical
Publication of AU672862B2 publication Critical patent/AU672862B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nanotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Medical Informatics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU56841/94A 1992-12-02 1993-12-01 Cyclodextrin and polymer based drug delivery system Ceased AU672862B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US07/984,445 US5332582A (en) 1990-06-12 1992-12-02 Stabilization of aminosteroids for topical ophthalmic and other applications
US984445 1992-12-02
US15516793A 1993-11-19 1993-11-19
US155167 1993-11-19
PCT/US1993/011651 WO1994012217A1 (fr) 1992-12-02 1993-12-01 Cyclodextrine et systeme de liberation de medicament a base de polymere

Publications (2)

Publication Number Publication Date
AU5684194A AU5684194A (en) 1994-06-22
AU672862B2 true AU672862B2 (en) 1996-10-17

Family

ID=26852057

Family Applications (1)

Application Number Title Priority Date Filing Date
AU56841/94A Ceased AU672862B2 (en) 1992-12-02 1993-12-01 Cyclodextrin and polymer based drug delivery system

Country Status (6)

Country Link
EP (1) EP0674528A4 (fr)
JP (1) JPH08503951A (fr)
CN (1) CN1103316A (fr)
AU (1) AU672862B2 (fr)
CA (1) CA2150554A1 (fr)
WO (1) WO1994012217A1 (fr)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW434023B (en) * 1995-09-18 2001-05-16 Novartis Ag Preserved ophthalmic composition
JP3940209B2 (ja) * 1996-11-14 2007-07-04 株式会社資生堂 可溶化化粧料
GB9711643D0 (en) * 1997-06-05 1997-07-30 Janssen Pharmaceutica Nv Glass thermoplastic systems
JP2002530313A (ja) * 1998-11-23 2002-09-17 ザ、プロクター、エンド、ギャンブル、カンパニー 皮膚消臭及び衛生化組成物
US6656456B2 (en) * 1998-11-23 2003-12-02 The Procter & Gamble Company Skin deodorizing compositions
KR20010113918A (ko) * 2000-03-10 2001-12-28 추후제출 후안부 안과 질환을 치료하고 예방하기 위한 방법 및 조성물
ATE416791T1 (de) 2000-05-02 2008-12-15 Theravance Inc Zusammensetzung die eine zyklodextrin und ein glykopeptid-antibiotikum enthält
WO2001083520A2 (fr) 2000-05-02 2001-11-08 Theravance,Inc Derives polyacides de glycopeptides
AU2001259816A1 (en) 2000-06-22 2002-01-02 Advanced Medecine, Inc. Polyhydroxy glycopeptide derivatives
US6872804B2 (en) 2000-06-22 2005-03-29 Theravance, Inc. Glycopeptide disulfide and thioester derivatives
UA75083C2 (uk) 2000-06-22 2006-03-15 Тераванс, Інк. Похідні глікопептидфосфонатів
AU2001259303A1 (en) 2000-06-22 2002-01-02 Advanced Medicine, Inc. Glycopeptide carboxy-saccharide derivatives
WO2002026237A1 (fr) * 2000-09-26 2002-04-04 Nisshin Pharma Inc. Preparation liquide de prednisolone phosphate de sodium
WO2002092106A1 (fr) * 2001-05-11 2002-11-21 Pacific Pharmaceuticals Limited Composition pharmaceutique destinee a masquer le gout de certains medicaments
EP2305308A1 (fr) * 2003-04-18 2011-04-06 Advanced Medicine Research Institute Remèdes à des affections, à usage ophtalmique
US6933289B2 (en) 2003-07-01 2005-08-23 Allergan, Inc. Inhibition of irritating side effects associated with use of a topical ophthalmic medication
WO2006040839A1 (fr) * 2004-10-15 2006-04-20 Advanced Medicine Research Institute Gouttes oculaires et trousses de traitement de maladies oculaires
JP2007177149A (ja) * 2005-12-28 2007-07-12 Shield Lab:Kk チオクト酸又はジヒドロリポ酸と分岐鎖シクロデキストリンとの包接化合物
US20070202186A1 (en) 2006-02-22 2007-08-30 Iscience Interventional Corporation Apparatus and formulations for suprachoroidal drug delivery
DK2234614T3 (da) * 2007-12-21 2013-02-11 Aop Orphan Pharmaceuticals Ag Farmaceutisk sammensætning til parenteral administration af et ultrakort virkende beta-receptorblokerende middel
US10980818B2 (en) 2009-03-06 2021-04-20 Sun Pharma Global Fze Methods for treating ocular inflammatory diseases
US10201548B2 (en) * 2009-03-06 2019-02-12 Sun Pharma Global Fze Methods for treating ocular inflammatory diseases
EP3520749A1 (fr) 2010-10-15 2019-08-07 Clearside Biomedical, Inc. Dispositif d'accès oculaire
BR112015010566A2 (pt) 2012-11-08 2017-07-11 Clearside Biomedical Inc métodos e dispositivos para o tratamento de doenças oculares em indivíduos humanos
US20150374832A1 (en) * 2013-02-12 2015-12-31 Ys Pharm Tech Epinephrine formulations for medicinal products
WO2014179698A2 (fr) 2013-05-03 2014-11-06 Clearside Biomedical, Inc. Appareil et procédés pour une injection oculaire
US10010447B2 (en) 2013-12-18 2018-07-03 Novartis Ag Systems and methods for subretinal delivery of therapeutic agents
CN103990137A (zh) * 2014-04-30 2014-08-20 福建融和药业有限公司 一种粘膜粘附性聚合物眼用药物的缓释剂
US10390901B2 (en) 2016-02-10 2019-08-27 Clearside Biomedical, Inc. Ocular injection kit, packaging, and methods of use
WO2017192565A1 (fr) 2016-05-02 2017-11-09 Clearside Biomedical, Inc. Systèmes et méthodes pour l'administration de médicaments par voie ophtalmique
IL264764B2 (en) 2016-08-12 2024-02-01 Clearside Biomedical Inc Devices and methods for adjusting the insertion depth of a drug administration needle
CN109136177B (zh) * 2018-08-03 2021-09-17 湖南大学 一种地塞米松缓释体系以及一种成骨分化诱导液和应用
RU2740287C1 (ru) * 2019-08-30 2021-01-12 Федеральное государственное бюджетное образовательное учреждение высшего образования "Московский государственный университет имени М.В. Ломоносова" (МГУ) 3д-матриксная структура для доставки лекарственных препаратов
CN115380899A (zh) * 2022-08-30 2022-11-25 陕西科技大学 一种凝胶型腐植酸缓释农药及其制备方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4383992A (en) * 1982-02-08 1983-05-17 Lipari John M Water-soluble steroid compounds
WO1989006964A1 (fr) * 1988-02-08 1989-08-10 Insite Vision, Inc. Suspensions ophtalmiques
US4983586A (en) * 1987-12-30 1991-01-08 University Of Florida Pharmaceutical formulations for parenteral use

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ225045A (en) * 1987-07-01 1990-06-26 Janssen Pharmaceutica Nv Antiviral pharmaceutical compositions containing cyclodextrin and an antiviral agent
DE69006259T2 (de) * 1989-05-24 1994-06-09 Innovet Inc Hypoallergene anästhesierende/hypnotische steroide Arzneizubereitung.
GB9012663D0 (en) * 1990-06-07 1990-08-01 Erba Carlo Spa Galenic formulations containing cyclodextrins

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4383992A (en) * 1982-02-08 1983-05-17 Lipari John M Water-soluble steroid compounds
US4983586A (en) * 1987-12-30 1991-01-08 University Of Florida Pharmaceutical formulations for parenteral use
WO1989006964A1 (fr) * 1988-02-08 1989-08-10 Insite Vision, Inc. Suspensions ophtalmiques

Also Published As

Publication number Publication date
WO1994012217A1 (fr) 1994-06-09
JPH08503951A (ja) 1996-04-30
EP0674528A4 (fr) 1996-06-26
CA2150554A1 (fr) 1994-06-09
CN1103316A (zh) 1995-06-07
EP0674528A1 (fr) 1995-10-04
AU5684194A (en) 1994-06-22

Similar Documents

Publication Publication Date Title
AU672862B2 (en) Cyclodextrin and polymer based drug delivery system
US5538721A (en) Stabilization of aminosteroids for topical ophthalmic and other applications
Loftssona et al. Cyclodextrins in ophthalmic drug delivery
Loftsson et al. Cyclodextrins and topical drug delivery to the anterior and posterior segments of the eye
US5576311A (en) Cyclodextrins as suspending agents for pharmaceutical suspensions
AU674382B2 (en) Plasticized bioerodible controlled delivery system
JP5469458B2 (ja) 高分子ミセルクラスタ及びそれらの薬剤への使用
US5631297A (en) Anandamides useful for the treatment of intraocular hypertension, ophthalmic compositions containing the same and methods of use of the same
JP2007532648A (ja) 眼の後部へのドラッグデリバリー
JP3529142B2 (ja) シクロデキストリンを含むガレヌス製剤
Jarho et al. Modified β‐cyclodextrin (SBE7‐β‐CyD) with viscous vehicle improves the ocular delivery and tolerability of pilocarpine prodrug in rabbits
US20040152664A1 (en) Prednisolone compositions
WO2005011617A2 (fr) Formes posologiques a administrer par voie transmuqueuse pour systemes de liberation de produit chimique steroide dirige sur le cerveau
US5977180A (en) Anandamide analog compositions and method of treating intraocular hypertension using same
EP0676952B1 (fr) Systeme de liberation controlee bioerodable
AU743204B2 (en) Controlled release of ophthalmic compositions
EP2994109B1 (fr) Formulations ophtalmiques aqueuses à base d'azithromycine
Erdoğar et al. Cyclodextrins in drug delivery
CN115837027A (zh) 一种眼用地塞米松药物组合物
Bary Considerations in the use of cyclodextrins in the reformation of ophthalmic suspensions as solutions
Loftsson et al. 2-Hydroxypropyl-6-cyclodextrin: Properties and Usage

Legal Events

Date Code Title Description
MK14 Patent ceased section 143(a) (annual fees not paid) or expired